Advanced Therapy Medicinal Products (ATMPs) have the potential to transform patient outcomes in areas where no therapeutic options previously existed.
However, their rapid development introduces complex challenges for manufacturers-ranging from contamination-control requirements and sterility assurance to process standardization, scalability, and long-term sustainability.
In a recent article published by ASCCA, Maria Luisa Nolli and Cristina Zanini, Scientific Director at IWT Pharma, provide a comprehensive overview of the current ATMP landscape. Their contribution examines:
The insights presented are directly connected to the principles that guide IWT’s approach to contamination control in ATMP environments. These same principles underpin the development of ISOCELL, our dedicated isolator for cell and gene therapy processing, designed to support consistency, operator protection and aseptic integrity across critical workflows.
Read the full article and contact us at marketing@iwtpharma.com to discuss how these considerations can support your ATMP processes.
CORPORATE
ITALY
FRANCE
GERMANY
UK
CHINA